摘要
为了解可溶性白细胞介素－６受体（ｓＩＬ－６Ｒ）在浆细胞病中的作用和意义，运用酶联配基免疫检测方法测定了６２例多发性骨髓瘤（ＭＭ）、５例巨球蛋白血症、１例μ重链病患者及１５例正常对照者血清ｓＩＬ－６Ｒ浓度。结果表明，Ⅱ、Ⅲ期ＭＭ患者、巨球蛋白血症患者血清ｓＩＬ－６Ｒ明显高于正常对照（Ｐ＜０．０１），Ⅰ期ＭＭ患者血清ｓＩＬ－６Ｒ浓度与对照组相差不显著（Ｐ＞０．０５）。在ＭＭ患者中，Ⅲ期患者血清ｓＩＬ－６Ｒ浓度最高、Ⅱ期患者次之，Ⅰ期患者最低（Ｐ值均＜０．０１）。此外还发现，不同Ｍ蛋白类别组之间血清ｓＩＬ－６Ｒ浓度无明显差异（Ｐ值均＞０．０５）。提示血清ｓＩＬ－６Ｒ浓度可作为ＭＭ患者反映病情的一个良好指标，而在其他浆细胞病中的意义有待于进一步研究。
It has been proven that interleukin 6 (IL 6) is the key growth factor for myeloma cells in vitro and in vivo. Binding of serum soluble IL 6 receptor (sIL 6R) with IL 6 can promote the biological effects of IL 6. To investigate the significance of serum sIL 6R in plsma cell dyscrasias (PCD), we determined serum sIL 6R concentrations in 62 patients with multiple myeloma (MM), 5 with macroglobulinemia, 1 with mu heavy chain disease and 15 healthy controls by using ligand immunoenzyme assay. The results showed that serum sIL 6R concentrations in macroglobulinemia and MM at stage Ⅱ and stage Ⅲ were significantly higher than these in MM at stage Ⅰ and healthy controls ( P <0.01). Morever, serum sIL 6R concentrations in MM at stage Ⅲ were higher than those in MM at stage Ⅱ ( P <0.01). But there were no statistic difference in serum sIL 6R concentrations between normal controls and MM at stage Ⅰ ( P >0.05). And there were also no difference in serum sIL 6R concentrations among various M protein classes ( P >0.05). Our results indicated that sreum sIL 6R concentration is a useful marker in reflecting disease severity in MM. Its clinical significance in other PCD needs further investigation.
出处
《中华内科杂志》
CAS
CSCD
北大核心
1997年第2期94-96,共3页
Chinese Journal of Internal Medicine
